Gastroenterology Archives - Page 2 of 3

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis

Authors: B G Schultz, I Diakite, J A Carter, S J Snedecor, R Turpin Published: Journal of Managed Care & Specialty Pharmacy, 2021 View publication Background The efficacy of intravenous (IV) vedolizumab...

Steroid and antibiotic prescribing rates in UK patients with ulcerative colitis on vedolizumab vs anti-TNF

Authors: G Parkes, A Akbar, I Beales, M Buckley, T Creed, S Din, N Plevris, N Heggs, S Meadowcroft, M Wallington, A Fraser Published: Gut, 2021 View publication Abstract Introduction This study...

The development and use of a preliminary conceptual model of inflammatory bowel disease to facilitate patient reported outcome (PRO) instrument selection for a UK real world evidence study

Authors: A J Rylands, G Owen, J Toms, N Heggs, C Bottomley Published: Value in Health, 2017 View publication Objectives Inflammatory bowel disease (IBD) is chronic in its nature and impacts patients’...

UK clinical experience at 52 Weeks with Linaclotide for Irritable Bowel Syndrome with constipation

Authors: A Emmanuel, J McLaughlin, S McLain-Smith, M Rance, A Agrawal, P B Allen, N Arebi, S Brown, M Eugenicos, A D Farmer, Y Yiannakou Published: Therapeutic advances in gastroenterology, 2016 View...

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation

Authors: Y Yiannakou, A Agrawal, P B Allen, N Arebi, S R Brown, M P Eugenicos, A D Farmer, S McLain-Smith, J McLaughlin, D S Sanders, D Lawrance and A Emmanuel Published:...

A retrospective United Kingdom (UK) chart review of early Vedolizumab experience: Real-World treatment, effectiveness and safety in inflammatory Bowel Disease (REVIVE)

Authors: Fraser Cummings, Daniel R. Gaya, Peter Irving, Sreedhar Subramanian, Fiona Glen, Lucinda Frere-Scott, Dirk Demuth, Anna Rathmell, Glynn Owen Published: 2016 View publication

The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with Inflammatory Bowel Disease (IBD): The UK TRANSIT study

Authors: Sara McCartney, James O Lindsay, Richard K Russell, Daniel R Gaya, Ian Shaw, Charlie Murray, Tricia Finney-Hayward, Shaji Sebastian Published: Journal of Crohns and Colitis, 2017 View publication Background Paediatric patients...

Hospital resource use and cost associated with first-line anti-TNF therapy in patients with inflammatory bowel disease in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies

Authors: J Hickey, S Keshav, S Gaugris, R Arasaradnam Published: Journal of Crohn's and Colitis, 2017 View publication Background UK National Institute for Health and Care Excellence guidance states that if more...

Real world use of adalimumab: effects on corticosteroid treatment and hospital resource utilisation in UK patients with moderate/severe ulcerative colitis

Authors: G Watts, R Arasaradnam, A Sharma, A Awasthi, J Limdi, A Bishop-Bailey, S Mclain-Smith, T Finney-Hayward Published: Journal of Crohn's and Colitis, 2017 View publication Background Anti-TNF therapies are used to...

News